Jump to:
Ioana represents hospital systems, health care providers, pharmaceutical, biotechnology, and medical device companies, and technology and financial firms in high-stakes government investigations and civil litigation. Ioana’s litigation and enforcement practice spans antitrust, False Claims Act, securities and restructuring-related matters. Ioana also advises clients on federal and state merger reviews, conduct investigations, and antitrust risk and compliance.
Experience
- Representing hotel company in class action litigation involving claims of algorithmic price fixing.
- Representing music data company in litigation involving monopolization claims.
- Represented Welsh, Carson, Anderson & Stowe in litigation brought by the Federal Trade Commission and class action plaintiffs alleging antitrust violations in connection with acquisitions by portfolio company. Secured dismissal with prejudice.
- Represented University of Colorado Health (UCHealth) in its partnership with Parkview Health System.
- Represented Lantheus in its acquisition of Evergreen Theragnostics. In the transaction, Lantheus acquired OCTEVY™, a registrational-stage PET diagnostic imaging agent targeting neuroendocrine tumors, a portfolio of clinical and pre-clinical theranostic pairs, and Evergreen’s radioligand therapy manufacturing infrastructure, including a revenue-generating CDMO business.
- Represented Lantheus in its acquisition of Life Molecular Imaging. In the transaction, Lantheus acquired Neuraceq® (florbetaben F18 injection), an approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer’s disease, a robust Alzheimer’s disease radiodiagnostic commercial infrastructure, advanced R&D capabilities, and an established international footprint.
- Represented Convatec in its acquisition of Triad Life Sciences, a biotechnology company that develops, manufactures, and commercializes biologics for the treatment of acute or chronic wounds and other regenerative applications, including the first 510k cleared porcine placenta-derived extracellular matrix products.
- Represented Trinseo Materials Operating S.CA., and certain of its affiliates, in connection with a $1.1 billion innovative financing transaction addressing the Company’s 2024 senior secured term loans and $385 million of its 2025 unsecured bonds. Funds managed and advised by Oaktree, Angelo Gordon and Apollo provided the financing .
- Represented the independent director of Basic Energy Services, Inc. in connection with the investigation and pursuit of estate causes of action as part of Basic’s chapter 11 cases, involving more than $400 million of funded debt.
- Represented the Special Committee of the Board of Directors of Centric Brands, Inc. in connection with its investigation of potential claims belonging to the estate.
- Represented leading pharmaceutical and biotechnology companies in False Claims Act government enforcement actions and qui tam litigation.
- Represented investment management firms and executive of issuer in Securities and Exchange Commission investigations into potential violations of securities laws.